Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Address correspondence to: Anna P. Durbin, 624 North Broadway, Room 251, Baltimore MD 21205. Phone: 410.614.4736; Email: email@example.com.
First published August 26, 2019 - More info
Dengue virus (DENV) infection causes a characteristic pathology in humans involving dysregulation of the vascular system. In some patients with dengue hemorrhagic fever (DHF), vascular pathology can become severe, resulting in extensive microvascular permeability and plasma leakage into tissues and organs. Mast cells (MCs), which line blood vessels and regulate vascular function, are able to detect DENV in vivo and promote vascular leakage. Here, we showed that an MC-derived protease, tryptase, is consequential for promoting vascular permeability during DENV infection through inducing breakdown of endothelial cell tight junctions. Injected tryptase alone was sufficient to induce plasma loss from the circulation and hypovolemic shock in animals. A potent tryptase inhibitor, nafamostat mesylate, blocked DENV-induced vascular leakage in vivo. Importantly, in 2 independent human dengue cohorts, tryptase levels correlated with the grade of DHF severity. This study defines an immune mechanism by which DENV can induce vascular pathology and shock.
Abhay P.S. Rathore, Chinmay Kumar Mantri, Siti A.B. Aman, Ayesa Syenina, Justin Ooi, Cyril J. Jagaraj, Chi Ching Goh, Hasitha Tissera, Annelies Wilder-Smith, Lai Guan Ng, Duane J. Gubler, Ashley L. St. John
Dengue viruses (DENV) are the most common cause of mosquito-borne viral illness in the world, affecting approximately 400 million people annually. Symptomatic illness ranges from a mild, self-limiting febrile illness to one manifested by plasma leakage that can lead to vascular collapse and death. In this issue of the JCI, Rathore et al. report that DENV can cause mast cell degranulation independently of mast cell infection, resulting in the release of the vasoactive mediators chymase and tryptase. The authors showed that recombinant chymase and tryptase increased endothelial permeability in a dose-dependent manner in human microvascular endothelial cells. They went on to evaluate the tryptase inhibitor nafamostat mesylate in a mouse model for severe DENV viremia. Strikingly, the potential therapeutic prevented and reversed the tryptase-induced vascular permeability. As there are currently no licensed drugs for the treatment of dengue, these findings present a possible treatment modality for severe disease.
Nearly two-thirds of the world’s population are living in dengue-endemic regions and are at risk of acquiring the disease (1). Twenty-five percent of the estimated 400 million people who annually develop dengue infections present for clinical care (2). Common manifestations of severe dengue include thrombocytopenia and hemorrhagic symptoms and death. Epidemiologic studies suggest that severe dengue most commonly results from a secondary heterotypic dengue infection (3). It is thought that, during the primary dengue infection, dengue virus (DENV) binds a nonneutralizing heterotypic antibody. Next, the antibody-virus complex binds the Fcγ receptor and enters cells, a phenomenon known as antibody-dependent enhancement of infection (4, 5). Theoretically, enhanced infection of target cells results in greater viral replication and pathogenicity, with higher virus titers associated with more severe disease (6).
The process by which DENV causes endothelial cell dysfunction and vascular leak has long been investigated. In this issue, Rathore and colleagues identify a mechanism by which DENV promotes vascular pathology and shock (7). In severe dengue disease, plasma leakage occurs later in infection, after the waning of fever and viremia. As such, plasma leakage is likely due to host-immune or mediator-induced response as opposed to endothelial cell infection and consequent destruction (8). In contrast to other hemorrhagic fever viruses, such as Ebola, in which endothelial cells remain intact, Rathore et al. suggest that DENV causes separation of endothelial cell junctions, which results in plasma leakage (7).
It was long hypothesized that cytokine storm induced by crossreactive T cells stimulated during a second, heterotypic dengue infection mediates vascular leak syndrome. However, such a dramatic hemorrhagic manifestation can also occur in primary dengue infection in which crossreactive T cells are not present (9). In addition, treatment trials using corticosteroids to combat cytokine storm, thereby preventing or treating dengue-associated vascular leak syndrome, failed (10).
Rathore and colleagues reported high levels of chymase and tryptase in the blood of patients following dengue infection. Previously, high levels of both, but more specifically tryptase, have been correlated with more severe disease (11, 12). Mechanistically, the study authors hypothesize that tryptase induces increased vascular permeability and leakage by reducing the expression of the cellular adhesion molecule CD31 on endothelial cells, resulting in the loss of tight junctions. Importantly, the authors demonstrated the effect of tryptase in both in vitro and in vivo models (7).
Currently, the only treatment for dengue vascular leak syndrome is supportive care. Although a vaccine for the prevention of dengue has been licensed, it is only recommended for those who have previously had a dengue infection. While other vaccines are in clinical trials, unprevented cases of dengue still require treatment. For this reason, medications that can treat dengue and/or vascular leak complications are needed.
Recent evidence has also implicated the non-structural protein 1 (NS1) and mast cells as factors involved in causing endothelial dysfunction. NS1 mediates vascular leakage either through TLRs (13, 14) or by inducing the expression of human sialidases, resulting in the degradation of the endothelial glycocalyx and leading to vascular leak. Glasner et al. demonstrated that mice that received a cocktail comprising the sialidase inhibitor, a cathepsin inhibitor, and heparanase were protected from vascular leak induced by dengue (14). Rathore et al. show that there are likely other biologic contributors to the vascular leak syndrome in dengue. Notably, in the DENV mouse model, treatment with nafamostat mesylate for 24 to 48 hours reversed endothelial cell junction separation and resolved plasma leakage (7).
The work of Rathore et al. lays the groundwork for further evaluation of tryptase inhibition for limiting the adverse effects of severe dengue. One of the next steps toward finding a safe and effective drug for treating dengue-induced vascular leak syndrome is to evaluate nafamostat mesylate in human clinical trials. It is critical that these findings be translated into clinical action.
Conflict of interest: The author has declared that no conflict of interest exists.
Copyright: © 2019, American Society for Clinical Investigation.
Reference information: J Clin Invest. 2019;129(10):4072–4073. https://doi.org/10.1172/JCI131170.
See the related article at Dengue virus–elicited tryptase induces endothelial permeability and shock.